Fixed-dose oral direct thrombin inhibitor ximelagatran as an alternative for dose-adjusted warfarin in patients with non-valvular atrial fibrillation

被引：0
|
作者：
Olsson, BB
Petersen, P
机构：
[1] Univ Lund Hosp, Dept Cardiol, S-22185 Lund, Sweden
[2] Univ Copenhagen Hosp, Med Ctr, Div Stroke, Hvidovre, Denmark
来源：
EUROPEAN HEART JOURNAL | 2001年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：330 / 330
页数：1
相关论文
共 50 条
  • [1] Ximelagatran, an oral direct thrombin inhibitor, compared with dose-adjusted warfarin for primary and secondary stroke prevention in patients with atrial fibrillation (SPORTIF V)
    Albers, GW
    [J]. STROKE, 2004, 35 (01) : 242 - 243
  • [2] Ximelagatran, an oral direct thrombin inhibitor, normalizes platelet activation and inhibits thrombin generation in patients with non-valvular atrial fibrillation.
    Wolzt, M
    Bostrom, SL
    Wollbratt, M
    Svensson, M
    Eriksson, UG
    Grind, M
    Sarich, TC
    [J]. PHARMACOTHERAPY, 2002, 22 (10): : 1365 - 1365
  • [3] Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
    Albers, GW
    Diener, HC
    Grind, M
    Halperin, JL
    Horrow, J
    Olsson, SB
    Petersen, P
    Vahanian, A
    Frison, L
    Nevinson, M
    Partridge, S
    [J]. LANCET, 2003, 362 (9397): : 1691 - 1698
  • [4] Inappropriate dose of direct oral anticoagulants therapy in patients with non-valvular atrial fibrillation
    Ito, M.
    Kaikita, K.
    Sueta, D.
    Ishii, M.
    Oimatsu, Y.
    Mitsuse, T.
    Arima, Y.
    Iwashita, S.
    Takahashi, A.
    Kanazawa, H.
    Kaneko, S.
    Kanemaru, Y.
    Kiyama, T.
    Yamabe, H.
    Tsujita, K.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 : 485 - 486
  • [5] Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation - Pooled analysis from the SPORTIF III and V studies
    Diener, HC
    [J]. CEREBROVASCULAR DISEASES, 2006, 21 (04) : 279 - 293
  • [6] Stroke prevention with the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation: final results of the pooled analysis of the SPORTIF III and V trials
    Olsson, SB
    [J]. EUROPEAN HEART JOURNAL, 2004, 25 : 643 - 643
  • [7] DIRECT ORAL ANTICOAGULANT EDOXABAN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: RESULTS OF DIRECT COMPARISON WITH WARFARIN
    Yavelov, I. S.
    [J]. KARDIOLOGIYA, 2020, 60 (08) : 124 - 129
  • [8] Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation
    Li-Saw-Hee, FL
    Blann, AD
    Lip, GYH
    [J]. STROKE, 2000, 31 (04) : 828 - 833
  • [9] Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients
    Nguyen, Elaine
    Egri, Florence
    Mearns, Elizabeth S.
    White, Charles M.
    Coleman, Craig I.
    [J]. PHARMACOTHERAPY, 2016, 36 (05): : 488 - 495
  • [10] THE DOSE OF DIRECT ORAL ANTICOAGULANTS AND STROKE SEVERITY IN PATIENTS WITH ACUTE ISCHEMIC STROKE AND NON-VALVULAR ATRIAL FIBRILLATION
    Kato, Y.
    Hayashi, T.
    Tanahashi, N.
    Takao, M.
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2018, 13 : 135 - 135
12345